MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.
MP Advisors unparalleled service includes:
- Financial Analysis;
- Competitive landscaping;
- Macro Analysis;
- Technology Transfer;
- Mergers & Acquisitions;
- Strategic planning;
- Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.
More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.
Publications found:
456
Sort by:
INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!
US$ 90.00
Incyte/ Novartis’ JAKAVI (ruxolitinib, JAK 1/2 inhibitor, Registered for MF; PhII ... triggers $40m milestone payment from Novartis (Ex-US rights), and INCY will received a second payment of $60m upon an achievement ... our report released on April 20, 2012 on INCY, titled “Cheers for INCY - JAKAVI Receives CHMP Nod!”
April 2012
2 pages
Lupin - Generic Fortamet Launched At Last, However Low Competition Window Shrinks
US$ 140.00
We withdraw our Positive Investment Alert (PIA) on Lupin after it re-launched generic Fortamet ($83m of annual US sales) in the US market. We issued ... the Preliminary Injunction (PI) on Lupin’s generic Fortamet. While we expected Lupin to launch it soon after the ruling, Lupin waited for the Federal Circuit ...
April 2012
3 pages
Merck - Celltrion filed first mAB Biosimilar in Europe: Remicade Challenged
US$ 90.00
Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...
April 2012
1 pages
AMGEN - Sharing, Shedding = Gaining!
US$ 90.00
News flow from Amgen’s (AMGN) pipeline highlights its focus to create maximum value through ... upfront $50m + low to mid single-digit royalty + equal profit sharing) could be a win-win for both the companies, but the ... read our report released on April 5th, 2012 on AMGN, titled “Sharing, Shedding = Gaining!”
April 2012
5 pages
REGENERON: Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!
US$ 90.00
... with Bayer for Ex-US, wet AMD) launch skyrocketed Regeneron (REGN); we expect other TRAP based products in the pipeline to sustain this ... Sanofi granted A Priority Review for ZALTRAP (VEGF trap/ aflibercept, R, mCRC – 2nd-line; PhII/ ... 5, 2012 on REGN, titled “Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!”
April 2012
5 pages
Roche - GSK - EMILIA: TDM1 ready to take over Tykerb
US$ 90.00
Today, Roche and ImmunoGen announced the topline data from EMILIA study ... T-DMI in this indication and this should come at the expense of GSK’s Tykerb, which is the current standard of care in this setting. This ...
March 2012
3 pages
Amylin Take Over Battle - A 25 -50% upside is very much there
US$ 90.00
... retaining full rights for Byetta/Bydureon franchisee from Lilly, Amylin became a target of acquisiton for global pharma giants. We see the ... bid going up much further, Amylin as a potential leader in the GLP-1 space, can very well justify ...
March 2012
1 pages
Merck - IMPROVE IT update - Appears trending favorably
US$ 90.00
Today, Merck announced that the Data Safety Monitoring Board has given a go-ahead signal to the IMPROVE-IT after it conducted a pre-specified second interim ... . The company has also indicated that the projected completion of IMPROVE IT by 2013 may change.
March 2012
1 pages
AMARIN - US Patent's Allowance gives AMR-101 the Lease of Life
US$ 140.00
... on its efficacy vs. GSK’s Lovaza (L, omega-3-acid ethyl esters, hypertriglyceridemia), allowance of patent till 2030 (application no. 12/052,598) has now removed the ... read our report released on Mar. 21st, 2011 on AMRN titled “US Patent’s Allowance gives AMR-101 the Lease of Life”.
March 2012
6 pages
Biocon – Pfizer Terminates the Insulin Deal – Good News For Biocon!
US$ 140.00
Pfizer terminated the Insulin deal with Biocon due to “changed priorities”. The termination of the deal fetches a sum of ~$200m for BIOS – probably more ... This is the upfront payment that Biocon received from Pfizer plus some money towards the termination of this deal. So a termination of this deal at a stage ...
March 2012
1 pages
Compulsory License: India Pharma’s solution to “Patent and Affordability”
US$ 140.00
Recently, Natco was granted the first Compulsory License in India for the anti-cancer drug ‘Nexavar’. In an early test of India’s requirement that patent monopolies will ... now give rise to opportunities for other large cap global pharma companies too, as they can also seek a CL for other best ...
March 2012
8 pages
Galapagos - Partnership Impact Sustainable?
US$ 140.00
Though deal with Abbott has added credibility to Galapagos’ GLPG0634 (PhII, an oral JAK1 inhibitor), there is still ... by 2014 could elevate GLPG, but our analysis of the impact of catalysts for 2012-13 suggest that …. GLPG0634 will be ... report released on 6th March on GLPG titled “Partnership Impact Sustainable?”
March 2012
6 pages
ACORDA - Walking Tall - Promise of Further Growth
US$ 140.00
Acorda (ACOR) has reached sustainable profitability through the sales of its marketed drug AMPYRA (dalfampridine, L, partnered with Biogen for EU, walking improvement in MS pts ... detail, please read our report released on 5th March, 2012 on Acorda titled “Walking Tall - Promise of Further Growth”
March 2012
6 pages
JAPAN DOMESTIC PHARMA- Competitive Landscape of Leading Therapy Classes - UPDATE
US$ 600.00
In this updated issue of ‘Japan-Domestic Pharma Market Summary’ for 2012, we present major 10 Thx Class in Japan which covers ~40% of total Japan domestic pharma market (~¥8.0 trillion). This will ... breakthroughs in each class – which includes products from all pharma companies operating in Japan including MNCs.
March 2012
27 pages
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
... Bayer for Japan royalties made FY11 a profitable year for Onyx pharma (ONXX), we do not expect it to be sustainable as high operating expenses (h43% YoY ... detail, please read our report released on 2nd Mar., 2012 on Onyx Pharma titled “Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!”
March 2012
4 pages
ROCHE - CHUGAI, RoActemra monotherapy Superior to Humira: ADACTA Study
US$ 90.00
In a Ph IV ADACTA monotherapy study, RoActema has shown superior improvement ... the biologic RA market (~ $10B). The data should support Roche’s sNDA for 1st line approval in the US (submitted in December ... in EU where Actemra is already approved in first line, Roche will file for a label change based on this data.
March 2012
2 pages
Bristol-Myers Squibb - Eliquis: FDA Decision Date Extended by Three Months
US$ 90.00
... BMY, the USFDA has extended the review period for Eliquis by 3 months (new PDUFA June 28th). At this ... has not announced any advisory committee to discuss Eliquis approval, but one may not rule out ... concerns over safety of Dabigatran. This delay in Eliquis approval, will obviously give some additional time for ...
February 2012
2 pages
GALAPAGOS - Santa Arrives – Late but With Bounty!
US$ 90.00
Today’s exclusive global agreement of Galapagos’ (GLPG) GLPG0634 (PhII, RA, oral JAK1 inhibitor) with a veteran player in ... , please read our report released on 29th February on GLPG titled “Santa Arrives – Late but With Bounty!”
February 2012
3 pages
INCYTE: Testing Time Ahead For JAKAFI
US$ 140.00
While the commercial challenge for Incyte (INCY) in US has just begun (reported only $2m net sales since ... , please read our report released on February 28, 2012 on INCY, titled “Testing Time Ahead For JAKAFI”.
February 2012
3 pages
DAIICHI SANKYO - Growth Story Remains Intact!
US$ 90.00
... rating on Daiichi Sankyo (DS) while revising down 12-months TP to ¥1,850 on account of incorporating likely impact of Ranbaxy settlement cost and tax reforms in Japan. Going forward ...
February 2012
2 pages
RANBAXY - Teva Partnership Hurts
US$ 140.00
... the unexpectedly high payment of ~$150m to Teva under the Lipitor generic agreement. Ranbaxy generated ~$300m from generic Lipitor that ... (1) Daiichi-Ranbaxy likely to become the largest generic company in Japan generics market (2) leveraging of Ranbaxy’s emerging market infrastructure (especially India) to ...
February 2012
6 pages
VIVUS: Potential for Adding More Weight in April
US$ 140.00
... safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, ... approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”
February 2012
9 pages
REGENERON: Marching Towards Profitability!
US$ 140.00
... Lucentis)! REGN should finally evolve from a Rising Star to become a profitable Biotech from 2012 onwards on the strength of its pipeline and ... , please read our report released on February 17, 2012 on REGN, titled “Marching Towards Profitability!”
February 2012
8 pages
ALEXION: Orphan Drugs and Innovative Biologics = Irresistible Combination!
US$ 140.00
... beyond soliris and experience in developing and marketing orphan drugs should increase its value beyond Genzyme… For more ... on February 15, 2012 on ALXN, titled “Orphan Drugs and Innovative Biologics = Irresistible Combination!”. Key words: Alexion, Acute Hormonal Rejection , Atypical Hemolytic Uremic ...
February 2012
6 pages
SUN PHARMA - Strong Base Business; Protonix Liability Not A Major Concern
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after it’s higher ... to note that FY12 performance represents purely the base business with no one off upsides. Future growth ... new target price by applying a PE of 20x on FY13 base business earnings, valuing upcoming Para IVs at Rs. 25 per share ...
February 2012
6 pages
CIPLA, Withdrawing Positive Investment Alert - Structural Issues Loom Large
US$ 140.00
We withdraw our Positive Investment Alert post the dismal Q3 FY12 result that highlights Cipla’s structural issues. In addition, we believe that the supply of API of ... estimates by 18% and 12% in FY12 and FY13. We thus withdraw our Positive Investment Alert and reiterate our Market Perform rating with a target ...
February 2012
5 pages
VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!
US$ 140.00
... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...
February 2012
12 pages
DISHMAN - Result Does Not Change the Outlook
US$ 140.00
Dishman’s Q3 FY12 EBITDA was higher than our estimates owing to change in ... and Dishman Netherlands grew by 28% and 36% Y-o-Y respectively mainly due to a favorable forex. Carbogen remained flat in constant currency. In other words, this quarter does not ...
February 2012
5 pages
GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
US$ 140.00
Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”
February 2012
11 pages
AMGEN - Still Worth Holding!
US$ 90.00
Amgen (AMGN) has sufficient cash (total cash: $19.6b, Lt. Debt: $21.4b) and experience to ... -up, it is still trading at a favorable multiple against its peers. For more details, please read our report released on 9th Feb., 2012 titled “Still worth Holding!”
February 2012
7 pages
BIOGEN IDEC - Investing for Long-Term
US$ 140.00
Biogen Idec (BIIB) promises to enrich its revenue stream and MS franchise in 2012 ... detail, please read our report released on 8th Feb., 2012 on Biogen Idec titled “Investing for Long-Term”.
February 2012
9 pages